Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Tildrakizumab and the Development of a Concentration Response Curve of Tildrakizumab for Psoriasis Patients

NCT05683015 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT05683015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05683015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Tildrakizumab and the Development of a Concentration Response Curve of Tildrakizumab for Psoriasis Patients
Lead sponsor
University Hospital, Ghent
Phase
Phase 4
Overall status
Unknown status
Start date
August 22, 2022
Completion date
December 31, 2025
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris